Accent Microcell Ltd
Healthcare | Small Cap
Accent Microcell Ltd demonstrates robust financial health, characterized by exceptional growth and outstanding profitability. The company is expanding at a very rapid pace across sales, profits, and its asset base, indicating strong market demand and successful strategic execution. Its profitability is a key strength, with high margins and excellent returns on investment. Furthermore, the company operates with virtually no debt, giving it a superior level of long-term financial stability and very low risk. However, this rapid growth presents challenges in operational efficiency. A notable weakness is the significant amount of time it takes to collect payments from customers, which could strain cash flow. Additionally, the overall effectiveness of using its large capital base to generate sales is low. The company is heavily reinvesting its earnings into expansion, as shown by high capital spending and low dividend payouts. The future outlook is positive, driven by strong growth momentum, but hinges on managing operational efficiencies as it scales.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio5.60
- Profitability Ratio10.00
- Efficiency Ratio5.00
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio8.38
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Accent Microcell Ltd demonstrates robust financial health, characterized by exceptional growth and outstanding profitability. The company is expanding at a very rapid pace across sales, profits, and its asset base, indicating strong market demand and successful strategic execution. Its profitability is a key strength, with high margins and excellent returns on investment. Furthermore, the company operates with virtually no debt, giving it a superior level of long-term financial stability and very low risk. However, this rapid growth presents challenges in operational efficiency. A notable weakness is the significant amount of time it takes to collect payments from customers, which could strain cash flow. Additionally, the overall effectiveness of using its large capital base to generate sales is low. The company is heavily reinvesting its earnings into expansion, as shown by high capital spending and low dividend payouts. The future outlook is positive, driven by strong growth momentum, but hinges on managing operational efficiencies as it scales.
Overall Valuation Score
P/E RATIO (TTM)
23.12
Industry Median
36.13
Small Cap Median
35.79
P/E RATIO
24.25
P/B RATIO
3.21
Industry Median
6.08
Small Cap Median
6.08
P/S RATIO
3.03
Industry Median
5.75
Small Cap Median
5.17
Others
PEG RATIO
0.47
EV/EBITDA RATIO
16.71
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹334.1 as on May 29, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company is in a phase of exceptional and widespread growth. It is expanding at an extremely high rate across all major indicators, including revenue, operating profit, and earnings per share. This powerful growth trajectory is supported by a rapid expansion of its asset base, indicating strong market acceptance and successful execution of its expansion strategy. This is a primary strength of the company.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 24.81 | 18.67 | 24.87 | 7.72 | 31.7 |
| Operating Profit Growth Rate | 18.18 | 46.15 | 105.26 | 7.69 | 35.71 |
| Earnings Per Share (EPS) Growth | -59.08 | 105.99 | 52.18 | 9.63 | 32.66 |
| Asset Growth Rate | 17.28 | 16.84 | 84.68 | 11.22 | 41.23 |
| Net Income Growth Rate | 20 | 100 | 150 | 10 | 33.33 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics present a mixed view, resulting in an average score. On the positive side, key per-share value indicators like earnings and book value show healthy growth. However, this is contrasted by low direct returns to shareholders in the form of dividends. The company is also undertaking very high levels of capital expenditure, which signifies a strategy focused on aggressive reinvestment for future growth rather than immediate shareholder payouts.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 4.62 | 9.23 | 14.68 | 15.71 | 18.33 |
| Cash Earnings Per Share (Cash EPS) | 7.69 | 12.31 | 16.19 | 17.62 | 20.42 |
| Book Value Per Share | 24.62 | 38.46 | 78.1 | 92.86 | 115 |
| Dividend Per Share (DPS) | 0.72 | 0.66 | 0.88 | 0.83 | 0.91 |
| Capital Expenditures (CapEx) | 4 | 4 | 13 | 37 | 87 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability is exceptional across all measures. It is highly effective at turning revenue into profit, as shown by its excellent margins. The returns it generates on the money invested by shareholders (ROE) and on its overall capital base (ROCE) are outstanding. This indicates superior management performance, a strong competitive position in the healthcare services sector, and highly efficient use of its resources to create value.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 5.42 | 7.61 | 14.23 | 14.34 | 14.9 |
| Return on Capital Employed (ROCE) | 19 | 27 | 31 | 24 | 25 |
| Return on Equity (ROE) | 18.75 | 24 | 18.29 | 16.92 | 15.94 |
| Return on Assets (ROA) | 13.68 | 17.12 | 19.02 | 18.42 | 17.7 |
| Operating Margin | 7.83 | 9.64 | 15.85 | 15.85 | 16.33 |
| Net Margin | 3.61 | 6.09 | 12.2 | 12.45 | 12.61 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's operational efficiency is a mixed bag, with an overall average performance. It is good at using its fixed assets to generate sales. However, there are significant weaknesses, particularly the very long time it takes to collect payments from customers, which can tie up cash. Furthermore, the overall efficiency in using its total capital to generate revenue is poor. These inefficiencies are notable areas of concern.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 5.53 | 6.35 | 8.48 | 5.52 | 6.58 |
| Inventory Turnover Ratio | 4.36 | 4.44 | 5.6 | 6.78 | 9 |
| Receivables Turnover Ratio | 11.07 | 8.38 | 5.86 | 4.45 | 4.47 |
| Days Sales in Inventory Ratio | 83.72 | 82.21 | 65.18 | 53.83 | 40.56 |
| Receivable Days | 32.97 | 43.56 | 62.29 | 82.02 | 81.66 |
| Capital Turnover Ratio | 4.26 | 3.55 | 1.49 | 1.35 | 1.26 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to meet its financial obligations is outstanding. With earnings far exceeding its interest payments, the risk of defaulting on its minimal debt is virtually non-existent. Similarly, profits provide a very large cushion for its dividend payments. This demonstrates superior financial security and a very high quality of earnings, ensuring that its commitments to both creditors and shareholders are extremely safe.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 3.67 | 6 | 38 | N/A | 59 |
| Equity Dividend Coverage Ratio | 5.56 | 12.5 | 14.29 | 16.67 | 20 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's long-term financial stability is outstanding and represents a key strength. It operates on a virtually debt-free basis, financing its assets almost entirely through equity. This conservative financial structure means the company has an extremely low risk of financial distress from debt obligations. This position provides maximum long-term security and financial independence, making it highly resilient to economic downturns.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.18 | 0.1 | 0.01 | 0 | 0 |
| Debt to Equity Ratio | 0.22 | 0.11 | 0.01 | 0 | 0 |
| Equity Ratio | 0.82 | 0.9 | 0.99 | 1 | 1 |
| Debt To Asset Ratio | 0.07 | 0.05 | 0.01 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company exhibits a very strong capacity to meet its short-term financial obligations. Its holdings of current and quick assets relative to its immediate liabilities are exceptionally high, indicating a substantial financial cushion and minimal short-term risk. This strong position is primarily built on its asset base. A point of relative weakness is that the cash generated directly from its core operations provides less coverage for its current debts, even though the overall liquidity picture remains robust.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.16 | 1.45 | 4.43 | 5.15 | 3.67 |
| Quick Ratio | 0.44 | 0.68 | 3.59 | 4.1 | 2.97 |
| Cash Ratio | 0.05 | 0.04 | 1.83 | 1.56 | 0.44 |
| Operating Cash Flow Ratio | 0.27 | 0.15 | 0.28 | 0.77 | 0.42 |
Current Ratios
Quick Ratios
Cash Ratios
Operating Cash Flow Ratios
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.01 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 4 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 5 | Kilitch Drugs (India) Ltd | 6.61 | 21.54 | Neutral | 37.00 | 9.27 | 30.00 |
| 6 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 7 | SMS Lifesciences India Ltd | 6.59 | 21.20 | Undervalued | 45.00 | 70.68 | 19.00 |
| 8 | Infinium Pharmachem Ltd | 6.42 | 26.90 | Neutral | 22.00 | 6.43 | 14.00 |
| 9 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 32.19 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -272.47 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | BPL Ltd | 5.46 | -31.11 | Neutral | -4.82 | -3.00 | -8.55 |
| 13 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
| 18 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
Management effectiveness is mixed. The company demonstrates outstanding financial performance with exceptional growth in sales and profits, coupled with significantly improving profitability margins. Financial prudence is a major strength, evidenced by a drastic reduction in debt and a very strong interest coverage ratio. However, these strengths are offset by considerable weaknesses in operational efficiency. A sharp increase in the cash conversion cycle and a significant divergence between net profit and cash from operations indicate poor working capital management and low-quality earnings. While growth and profitability are strong, the inability to convert these profits into cash is a significant concern.
Financial Performance & Growth
The company has demonstrated excellent financial performance, characterized by robust and accelerating growth in both revenue and profitability. Annual sales have consistently grown, with a compound annual growth rate (CAGR) of 21% over the last five years. The profit growth is even more impressive, with a five-year CAGR of 54% and a remarkable 153% year-over-year increase in the latest fiscal year (FY24). This growth is supported by a substantial improvement in operational efficiency. The Operating Profit Margin (OPM) has expanded from 5% in FY19 to 16% in FY24, indicating strong cost control and pricing power. Profits are primarily driven by core operations, as the contribution from other income remains low relative to the profit before tax.
Capital Efficiency & Returns
Capital efficiency shows a mix of strengths and weaknesses. On the positive side, Return on Capital Employed (ROCE) has shown a strong upward trend, improving from an average of 17.5% in FY20-21 to 31% in FY24, indicating highly productive use of capital in generating profits. However, the company's working capital management has deteriorated significantly. The Cash Conversion Cycle (CCC) has lengthened substantially, rising to 114 days in FY24 from an average of 74 days in the preceding two years. This increase is primarily due to a rise in debtor days and a sharp reduction in days payable, suggesting that more cash is being tied up in operations. The Return on Equity (ROE) stands at a healthy 18.4%.
Financial Health & Prudence
The company's financial health and prudence are outstanding. Management has been highly effective in deleveraging the balance sheet. Borrowings have been consistently reduced over the years, leading to a very low debt-to-equity ratio of just 0.08 in FY24, down from 1.30 in the FY19-21 period. This demonstrates a strong commitment to maintaining a robust financial structure. The significant reduction in debt, combined with soaring operating profits, has resulted in an exceptionally strong Interest Coverage Ratio of 38x in FY24. This indicates a negligible risk of default on interest payments. The consistent, albeit low, dividend payout shows a practice of sharing profits while retaining the majority of earnings for reinvestment to fuel growth.
Shareholding & Ownership Structure
The ownership structure reflects strong promoter conviction but limited institutional participation. The promoter holding is stable and projected to remain around a solid 55%, which indicates long-term commitment and alignment of interests with minority shareholders. This level of 'skin in the game' is a positive indicator of management's confidence in the company's future prospects. However, institutional ownership remains very low. Foreign Institutional Investors (FIIs) hold a negligible stake, and while Domestic Institutional Investors (DIIs) have a presence, their holding is minimal at 3.59% in the latest data. This low level of institutional investment may suggest that the company, possibly due to its small size or recent listing, has not yet attracted significant attention from larger market participants.
The overall risk profile is moderate. The primary risk stems from poor accounting quality, highlighted by a severe disconnect between reported profits and actual cash generation. In FY24, the company generated only ₹11 Cr in cash from operations against a net profit of ₹30 Cr. This discrepancy, driven by a deteriorating working capital cycle and a sharp increase in receivables, raises significant questions about the quality and sustainability of earnings. While the company has very low financial risk due to minimal debt and strong coverage ratios, the operational risk related to cash flow conversion is high. The compelling growth story is clouded by the fundamental risk of non-cash-backed profits.
Accounting Quality
There is a significant red flag related to the quality of earnings, evidenced by the large and growing divergence between reported profit and cash flow from operations (CFO). In the most recent fiscal year (Mar 2024), net profit stood at ₹30 Cr, while CFO was only ₹11 Cr. This indicates that only 37% of profits were converted into actual cash, a sharp deterioration from previous years. This trend is a classic indicator of potential issues in revenue recognition or difficulty in collecting payments from customers, as reflected in the ballooning debtor days. The CFO to Operating Profit ratio has also fallen to a weak 44% in FY24.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe